Please login to the form below

asthma drug

This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.

FDA rejects GSK’s Nucala for COPD

There was bad if not unexpected news for GlaxoSmithKline late Friday, after the FDA refused to extend the indications of its asthma drug Nucala to include chronic obstructive pulmonary disorder (COPD). ... Meanwhile, Nucala isn’t the first drug in the

Latest news

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

AstraZeneca and partner Amgen have picked up a breakthrough designation from the FDA for tezepelumab, a drug that AZ claims could be a “best in disease” therapy for severe asthma. ... for severe asthma in Europe in January but just failed a test in
New cancer drugs can’t quite plug the revenue hole at AZ

Overall sales fell 5% to $10.33bn, however, thanks to generic competition taking another chunk out of cholesterol drug Crestor (rosuvastatin) sales, particularly in Europe and Japan. ... Other bright spots for AZ included the continued growth if
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

News from pharma, biotech and healthcare. Limited NICE approval for AZ’s asthma drug Fasenra. ... However, the UK's cost-effectiveness watchdog says the drug should only be used in limited circumstances for eosinophilic asthma, when usual therapies
PMCPA takes AZ to task over asthma drug press release

A complaint filed by GlaxoSmithKline against AstraZeneca about a press release for its severe asthma drug Fasenra, which competes with GSK’s Nucala, has been largely upheld by the industry governing ... The spat comes as Fasenra and Nucala (mepolizumab)
Dermira craters as acne drug fails late-stage test

The topical drug, which acts to inhibit sebum production in the skin by blocking acetyl coenzyme-A carboxylase, had been expected to make inroads into the $3bn US market for acne ... s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new

More from news
Approximately 2 fully matching, plus 108 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)
US health reforms

In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by
Building BRICs: pharma's key emerging markets are becoming giants

In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Enterprise Therapeutics appoints CEO

He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,
Former RBS head takes the reins as GSK chair

the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Account Director development role to Business Director, H...: Excellent package

Account Director: Competitive Salary Offered

Account Manager / Account Director: Competative

Account Director – Healthcare Marketing – Berks: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Business Director: Competitive Salary Offered

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Manager: Competitive Salary Offered

Account Director, Medical Education: Salary TBC

Global Business Development Director – Health Education: excellent commission

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Director – Healthcare PR – Global Agency: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Account Director, Healthcare Marketing Agency: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Senior Medical Writer: Salary TBC

Associate Director: £75, 000-90, 000

Account Director – Health Policy – Global Agency: Salary TBC

Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch: ...